Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin

Prostate

Volumn 71, Issue 11, 2011, Pages 1216-1224

  Xu, Shuping ^a   Weihua, Zhang ^b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b University of Houston   (United States)

^c NONE   (United States)

Author keywords

autophagy; drug resistance; EGFR; kinase independent function; prostate cancer

Indexed keywords

CALPAIN; CASPASE 3; CASPASE 7; DOXORUBICIN; GLUCOSE; MICROTUBULE ASSOCIATED PROTEIN 1; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79958209353     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21337     Document Type: Article

References (48)

1. Khalil MY, Grandis JR, Shin DM,. Targeting epidermal growth factor receptor: Novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003; 3 (3): 367-380. (Pubitemid 36748047)
2. Herbst RS, Sandler AB,. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004; 6 (Suppl 1): S7-S19.
3. Letellier G, Perez MJ, Yacoub M, Levillain P, Cussenot O, Fromont G,. Epithelial phenotypes in the developing human prostate. J Histochem Cytochem 2007; 55 (9): 885-890. (Pubitemid 47293834)
4. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L,. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113 (4): 619-628. (Pubitemid 40038739)
5. Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC,. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 71 (6): 751-760.
6. Sherwood ER, Lee C,. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995; 13 (5): 290-296.
7. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM,. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90 (2): 449-454. (Pubitemid 38250644)
8. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F,. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8 (11): 3438-3444. (Pubitemid 35340719)
9. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C,. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1 (5): 545-550.
10. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB,. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007; 7: 142.
11. Ewald JA, Wilkinson JC, Guyer CA, Staros JV,. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res 2003; 282 (2): 121-131. (Pubitemid 36262032)
12. Kang CS, Zhang ZY, Jia ZF, Wang GX, Qiu MZ, Zhou HX, Yu SZ, Chang J, Jiang H, Pu PY,. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther 2006; 13 (5): 530-538.
13. Nagy P, Arndt-Jovin DJ, Jovin TM,. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 2003; 285 (1): 39-49. (Pubitemid 36390154)
14. Wu X, Deng Y, Wang G, Tao K,. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res 2007; 138 (1): 56-63. (Pubitemid 46227454)
15. Dancey JE, Freidlin B,. Targeting epidermal growth factor receptor-Are we missing the mark ? Lancet 2003; 362 (9377): 62-64. (Pubitemid 36835824)
16. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, Magnuson T,. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995; 269 (5221): 230-234.
17. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA, Lee DC,. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 1994; 8 (4): 399-413. (Pubitemid 24071181)
18. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC,. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13 (5): 385-393. (Pubitemid 351609444)
19. White E, DiPaola RS,. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15 (17): 5308-5316.
20. Yue Z, Jin S, Yang C, Levine AJ, Heintz N,. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100 (25): 15077-15082. (Pubitemid 37518019)
21. Koneri K, Goi T, Hirono Y, Katayama K, Yamaguchi A,. Beclin 1 gene inhibits tumor growth in colon cancer cell lines. Anticancer Res 2007; 27 (3B): 1453-1457. (Pubitemid 46807222)
22. Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M, Wei L,. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 2009; 5 (8): 1131-1144.
23. Cao Q, Yu C, Xue R, Hsueh W, Pan P, Chen Z, Wang S, McNutt M, Gu J,. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int J Biochem Cell Biol 2008; 40 (2): 272-283. (Pubitemid 350137879)
24. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S,. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 2008; 15 (17): 1233-1239.
25. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ,. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996; 2 (9): 1627-1636. (Pubitemid 126447459)
26. Mizushima N,. Methods for monitoring autophagy using GFP-LC3 transgenic mice. Methods Enzymol 2009; 452: 13-23.
27. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU,. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8 (10): 1124-1132. (Pubitemid 44473608)
28. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L,. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23 (3): 455-460. (Pubitemid 46224221)
29. Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nole F, Verweij F, Matei V, De Cobelli O,. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: Quality of life and surrogate markers of activity. Anticancer Drugs 2007; 18 (8): 949-954. (Pubitemid 47220714)
30. Gravis G, Bladou F, Salem N, Goncalves A, Esterni B, Walz J, Bagattini S, Marcy M, Brunelle S, Viens P,. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008; 19 (9): 1624-1628.
31. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF,. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007; 100 (4): 765-769. (Pubitemid 47360196)
32. Marks RA, Zhang S, Montironi R, McCarthy RP, MacLennan GT, Lopez-Beltran A, Jiang Z, Zhou H, Zheng S, Davidson DD, Baldridge LA, Cheng L,. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. Prostate 2008; 68 (9): 919-923. (Pubitemid 351794156)
33. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C,. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77 (6): 855-861. (Pubitemid 28101770)
34. Traish AM, Morgentaler A,. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: A potential molecular switch for tumour growth. Br J Cancer 2009; 101 (12): 1949-1956.
35. Goel S, Hidalgo M, Perez-Soler R,. EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 2007; 6 (4): 305-320. (Pubitemid 350104820)
36. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ,. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110 (Pt 2): 113-121. (Pubitemid 27075856)
37. Harari PM, Huang SM,. Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results ? Int J Radiat Oncol Biol Phys 2004; 58 (3): 976-983. (Pubitemid 38221159)
38. Jost M, Gasparro FP, Jensen PJ, Rodeck U,. Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation-Differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression. J Invest Dermatol 2001; 116 (6): 860-866. (Pubitemid 32554369)
39. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P, Venuta S, Bianco AR, Abbruzzese A,. EGF activates an inducible survival response via the RAS→Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003; 10 (2): 218-229. (Pubitemid 36553464)
40. Leu CM, Chang C, Hu C,. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000; 19 (13): 1665-1675. (Pubitemid 30200968)
41. Burdak-Rothkamm S, Rube CE, Nguyen TP, Ludwig D, Feldmann K, Wiegel T, Rube C,. Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol 2005; 181 (3): 197-204.
42. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, Nyati MK,. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007; 26 (23): 3431-3439. (Pubitemid 46788888)
43. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F,. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16 (Suppl 4): iv61-68. (Pubitemid 43084948)
44. Abal M, Andreu JM, Barasoain I,. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3 (3): 193-203. (Pubitemid 36565761)
45. Liu S, Bishop WR, Liu M,. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003; 6 (4): 183-195. (Pubitemid 37129918)
46. Higgins LH, Withers HG, Garbens A, Love HD, Magnoni L, Hayward SW, Moyes CD,. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta 2009; 1787 (12): 1433-1443.
47. Bajgelman MC, Strauss BE,. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 2006; 66 (13): 1455-1462. (Pubitemid 44350371)
48. Cheung EC, Vousden KH,. The role of p53 in glucose metabolism. Curr Opin Cell Biol 2010; 22 (2): 186-191.